ArticleNature communications2025
SPA-PNN ligand for the kinetic resolution of carbocyclic and heterocyclic spiranes by asymmetric hydrogenation.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bulky alkali metal cations enabled highly efficient iridium-catalyzed asymmetric hydrogenation for C-N axial chiralityChemical science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The chiral carbocyclic and heterocyclic spirane scaffolds are widely present in natural products and pharmaceutical molecules. Efficient, concise, and enantioenriched synthesis of these structures is a significant objective in both academic and industrial fields. Here, we design and synthesize a series of chiral SPA-PNN ligands, which are used to kinetically resolve racemic spirocyclic 1,3-diketones and their analogs via Ir-catalyzed asymmetric direct hydrogenation to afford the corresponding chiral spirocyclic 1,3-diketones and chiral hydroxyspiroketones. This asymmetric transformation features broad substrate scope (four different types of spirocycle), low catalyst loading (S/C = 5000), and an excellent kinetic resolution efficiency (selectivity factor of up to 207). Notably, the resulting chiral products are successfully used in the total and formal synthesis of four natural products, and in the preparation of key synthetic intermediates for structurally attractive ligands. Furthermore, control experiments and DFT calculations enable the origin of the observed enantioselectivity to be elucidated.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.